Abstract:Castration resistant prostate cancer (CRPC) is a fatal disease. Androgen receptor pathway inhibitors, like enzalutamide, are initially effective but resistance eventually occurs, often associated to the emergence of aggressive neuroendocrine variants (NEPC). Even immunotherapy induced limited results in prostate cancer, governed by an immunosuppressive microenvironment. Therefore, effective therapies are needed. We here investigate in preclinical models a new approach aimed to revert castration resistance and simultaneously turn the immune milieu from "cold" to "hot", through the combination between enzalutamide and the drug GSK-126, which inhibits the epigenetic modulator EZH2. We show that enzalutamide and GSK-126 can synergize to restrain the growth of CRPC in vitro and in vivo. Moreover, this therapeutic combination efficiently reduced NEPC differentiation, in both subcutaneous and autochthonous in vivo models, increasing the rate of cured mice with regressed lesions. The antitumor efficacy observed in immunocompetent mice bearing subcutaneous syngeneic CRPC tumors was lost in immunodeficient mice, indicating a contribution of immune cells. Additional experiments in the TRAMP spontaneous mouse model revealed that the combination of enzalutamide and GSK-126 significantly induced cytotoxic activity and IFNγ production by tumor-specific CD8+ T cells, otherwise tolerant, and increased IL-17 production by CD4+ T cells. The two drugs did not directly modulate T cell activity in vitro, suggesting the importance of microenvironment accomplices in triggering these effects. These results promote the combined use of enzalutamide and GSK-126 to restrain CRPC growth and NEPC differentiation, and, simultaneously, to awake antitumor T cell response, opening new possibilities for immunotherapy in prostate cancer. Citation Format: Irene Fischetti, Botti Laura, Roberta Sulsenti, Valeria Cancila, Claudia Enriquez, Renata Ferri, Marco Bregni, Filippo Crivelli, Claudio Tripodo, Mario P. Colombo, Elena Jachetti. Combined therapy targeting AR and EZH2 restrains the growth of castration resistant prostate cancer by enhancing antitumor T cell response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2639.

Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer

18β-Glycyrrhetinic acid synergizes with enzalutamide to counteract castration-resistant prostate cancer by inhibiting OATP2B1 uptake of dehydroepiandrosterone sulfate

Combination of Sorafenib and Enzalutamide As a Potential New Approach for the Treatment of Castration-Resistant Prostate Cancer

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway

Olaparib and Enzalutamide Synergistically Suppress HCC Progression Via the AR-mediated Mir-146A-5p/brca1 Signaling.

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: an Asian Multiregional, Randomized Study.

Abstract 2639: Combined therapy targeting AR and EZH2 restrains the growth of castration resistant prostate cancer by enhancing antitumor T cell response

Preclinical Studies Show Using Enzalutamide is Less Effective in Docetaxel-Pretreated Than in Docetaxel-Naïve Prostate Cancer Cells

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response

Androgen-deprivation Therapy with Enzalutamide Enhances Prostate Cancer Metastasis Via Decreasing the EPHB6 Suppressor Expression.

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

Metformin in Overcoming Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Preclinical Study Using Androgen Receptor (AR) Degradation Enhancer to Increase Radiotherapy Efficacy Via Targeting Radiation-Increased AR to Better Suppress Prostate Cancer Progression

Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122.

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line

Targeting the Androgen Receptor (AR) with AR Degradation Enhancer ASC-J9® Led to Increase Docetaxel Sensitivity Via Suppressing the P21 Expression.

The JNK Inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells in Vitro and in Vivo and Inhibit Androgen Receptor Expression.

Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators